Alps Group Inc (Nasdaq: ALPS) grows FY 2026 revenue 44% to $4.9M

Rhea-AI Filing Summary

Alps Group Inc, an integrated biotechnology platform headquartered in Malaysia, reported fiscal year 2026 revenue of $4.9 million, up 44% year over year, driven by cellular therapy, medical testing, aesthetics services and healthcare products. Gross profit rose to $1.6 million, while gross margin declined to 32% from 39% as aesthetics services with profit-sharing and a changed revenue mix increased cost of sales.

The company recorded a net loss of $2.1 million, with basic and diluted loss per share of $(0.02) for both 2026 and 2025. Administrative expenses increased to $3.5 million, including $1,155,458 of professional fees related to its Business Combination and Nasdaq listing. Other operating income expanded to $1.3 million. Net cash used in operating activities was $2.6 million, partly offset by $2.9 million of cash from financing, leaving cash and cash equivalents of $0.6 million at March 31, 2026.

Alps highlighted completing its Business Combination with Globalink and starting to trade on Nasdaq under “ALPS,” advancing its MyImmune NK cell therapy and exosome programs, expanding MyGenome’s accreditation for whole genome sequencing under MS ISO 15189:2022, and collaborating to build a patient-derived organoid platform in Malaysia.

Filing Explained

The audited balance sheet adds capital deficiencies and director-related obligations to Alps’s reported operating results.

On August 7, 2026, Alps Group Inc furnished fiscal-year results whose audited balance sheet reported $3,230,001 of capital deficiencies as of March 31, 2026, adding a negative reported capital position to the operating results.

Form 6-K is used by a foreign private issuer to furnish material interim information; this filing furnishes a press release and states that the company filed its annual Form 20-F on August 6, 2026. The Form 20-F is the company’s annual report, so the disclosed annual-report filing is the completed reporting event while this page is the accompanying announcement.

The same balance sheet reported total liabilities of $10,199,391, including $4,398,453 classified as non-current amounts due to directors, $1,155,835 as current amounts due to directors, and a $125,528 warrant liability. These are specifically identified obligations and liability items, rather than new financing proceeds or cash available to common holders.

Key Figures

Revenue: 4,856,320 USD Net loss: 2,086,455 USD Gross margin: 32% +5 more

8 metrics

Revenue 4,856,320 USD For the fiscal year ended March 31, 2026; up 44% from 2025

Net loss 2,086,455 USD Loss for the financial year ended March 31, 2026

Gross margin 32% Fiscal year 2026 gross margin vs 39% in fiscal 2025

Gross profit 1,558,274 USD Gross profit for the fiscal year ended March 31, 2026

Net cash used in operating activities 2,575,649 USD Net cash used in operating activities for fiscal 2026

Cash and cash equivalents 607,473 USD Cash and cash equivalents at March 31, 2026

Capital deficiencies 3,230,001 USD Capital deficiencies as at March 31, 2026

Amount due to directors (non-current) 4,398,453 USD Non-current amount due to directors as at March 31, 2026

Key Terms

Business Combination, Natural Killer (NK) Cell Therapy, Patient-Derived Organoid (PDO) platform, MS ISO 15189:2022, +2 more

6 terms

Business Combination financial

"Completed the Business Combination with Globalink in October 2025"

A business combination happens when two or more companies join together to operate as one, like two friends merging their teams into a single group. This is important because it can change how companies grow, compete, and make money, often making them bigger and more powerful in the market.

Natural Killer (NK) Cell Therapy medical

"Advanced its Natural Killer (NK) Cell Therapy program, MyImmune"

A therapy that uses natural killer (NK) cells—a type of immune cell that can recognize and kill infected or abnormal cells—to treat disease, often cancer. NK cell therapies can use a patient’s own cells, donor cells, or engineered cells amplified and sometimes modified in a lab to boost their targeting and persistence; think of them as trained soldiers sent to find and destroy specific threats. It matters to investors because development progress, clinical trial results, manufacturing scale and regulatory approvals determine commercial potential and financial risk in this emerging biotech area.

Patient-Derived Organoid (PDO) platform medical

"to establish a clinically validated Patient-Derived Organoid (PDO) platform"

MS ISO 15189:2022 regulatory

"laboratory accreditation to include Whole Genome Sequencing under MS ISO 15189:2022"

A national adoption of ISO 15189:2022 is a formal standard that sets technical and quality-management requirements for medical laboratories, covering staff competence, equipment, processes and reporting. For investors, accreditation to this standard is like a lab having a trusted seal of reliability—affecting regulatory compliance, contract eligibility, reputational risk and the credibility of diagnostic or clinical trial data that can influence revenue and partnerships.

capital reorganization financial

"The Business Combination completed in October 2025 was accounted for as a capital reorganization"

warrant liability financial

"Warrant liability amounted to 125,528 USD within non-current liabilities"

Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.

FAQ

What were Alps Group Inc (ALPS) revenues for fiscal year 2026?

Alps Group Inc reported fiscal 2026 revenue of $4,856,320, a 44% increase from $3,371,037 in 2025. Growth was driven mainly by medical testing, laboratory and aesthetics services at $3,149,193, as well as cellular therapy and sales of medicine and healthcare products.

Did Alps Group Inc (ALPS) post a profit or loss in fiscal 2026?

Alps Group Inc recorded a net loss of $2,086,455 for the year ended March 31, 2026. Basic and diluted loss per share were $(0.02), the same as in 2025, reflecting higher administrative expenses partly offset by increased revenue and other operating income.

How did Alps Group Inc (ALPS) gross margin change in fiscal 2026?

Gross margin was approximately 32% in fiscal 2026, down from 39% in 2025. Management attributed this to greater contribution from aesthetics services, which include profit-sharing recorded in cost of sales, and an overall shift in the company’s revenue mix.

What cash position and cash flows did Alps Group Inc (ALPS) report for 2026?

At March 31, 2026, cash and cash equivalents were $607,473. Net cash used in operating activities totaled $(2,575,649), net cash used in investing was $(64,490), and financing activities generated $2,931,489, resulting in a net increase in cash of $291,350 for the year.

What strategic and R&D milestones did Alps Group Inc (ALPS) highlight for 2026?

Alps completed its Business Combination with Globalink and began trading on Nasdaq as “ALPS,” advanced its MyImmune NK cell therapy, explored expanded exosome therapies, gained WGS accreditation for MyGenome under MS ISO 15189:2022, and initiated a collaboration to establish a patient-derived organoid platform.

What does Alps Group Inc (ALPS) capital structure look like as of March 31, 2026?

As of March 31, 2026, Alps reported capital deficiencies of $3,230,001, with equity attributable to owners at $(2,924,618). Total liabilities were $10,199,391, including amounts due to directors of $4,398,453 non-current and $1,155,835 current, plus a warrant liability of $125,528.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/07/2026 - 04:16 PM Accepted by SEC EDGAR 08/07/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-42915

Alps Group Inc

(Registrant’s Name)

Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)

No. 1, Jalan 1/68F, Jalan Tun Razak

50400 Kuala Lumpur

Wilayah Persekutuan, Malaysia

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Information Contained in this Form 6-K Report

On August 7, 2026, Alps Group Inc (the “Company”) issued a press release announcing its financial results for the fiscal year ended March 31, 2026, a copy of which is being furnished as Exhibit 99.1 hereto.

Exhibits

Exhibit No.		Description
99.1		Press Release dated August 7, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alps Group Inc
Date: August 7, 2026	By:	/s/ Dr. Tham Seng Kong
	Name:	Dr. Tham Seng Kong
	Title:	Chief Executive Officer and Director

Exhibit 99.1

Alps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business Update

Revenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products

Began Trading on the Nasdaq Global Market Under the Ticker Symbol “ALPS” in October 2025, Marking the Company’s Transition to the U.S. Public Markets

KUALA LUMPUR, Malaysia – August 7, 2026 – Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its financial results for the year ended March 31, 2026, and provides a business update. The Company has filed its annual report on Form 20-F, including its audited financial statements for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (the “SEC”) on August 6, 2026. Alps’ Form 20-F can be accessed on the “Investors Relations” section of its website at https://investor.alps-holdings.com/, as well as on the SEC’s website at www.sec.gov. Shareholders may also request a hard copy of the Form 20-F annual report that includes audited financial statements, free of charge, by sending an e-mail to Alps’ IR firm at alps@kcsa.com.

“Fiscal year 2026 was a transformational year for Alps. We completed our Business Combination with Globalink Investment Inc. and began trading on the Nasdaq Global Market under the ticker symbol ‘ALPS,’ giving us a stronger platform to execute against our long-term strategy,” said Dr. Tham Seng Kong, Managing Director and Group Chief Executive Officer of Alps Group Inc. “At the same time, we grew revenue 44% year-over-year, advanced our cellular therapy pipeline and sharpened our research and development focus on the areas where we see the greatest opportunity to deliver value for patients and shareholders.”

Fiscal Year 2026 Business Highlights

	●	Completed the Business Combination with Globalink in October 2025 and began trading on the Nasdaq Global Market (Nasdaq) under the ticker symbol “ALPS”.
	●	Strengthened its leadership team with appointment of Cheing Lye-Ping (Penny) as Chief Financial Officer.
	●	Advanced its Natural Killer (NK) Cell Therapy program, MyImmune, completing the optimization phase and progressing toward process validation.
	●	Identified a potential expansion of its exosome-based therapeutic pipeline beyond its existing CELESOME(+) program, following a case series on nebulized exosome therapy in asthma and chronic obstructive pulmonary disease patients.

Recent Developments

	●	Expanded MyGenome Sdn. Bhd.’s laboratory accreditation to include Whole Genome Sequencing (WGS) under MS ISO 15189:2022, positioning MyGenome among a select group of genomics laboratories in Southeast Asia delivering WGS under internationally recognized clinical laboratory standards.
	●	Entered into a Research Consultancy and Collaboration Agreement, through subsidiary MyGenome Sdn. Bhd., to establish a clinically validated Patient-Derived Organoid (PDO) platform in Malaysia.
	●	Appointed Lee Hee Hang, a former Partner at Ernst & Young LLP, to the Board of Directors, bringing deep audit and financial governance expertise to the Company’s Audit and Compensation Committees.

Fiscal Year 2026 Financial Results

● Revenue increased 44% to $4.9 million for the year ended March 31, 2026, compared to $3.4 million for the year ended March 31, 2025.

○ Net loss for the year ended March 31, 2026 was $2.1 million, compared to $2.6 million for the year ended March 31, 2025.

	●	Net loss per share, basic and diluted, was $(0.02) for both the year ended March 31, 2026, and the year ended March 31, 2025.
	●	Gross profit increased to $1.6 million for the year ended March 31, 2026, compared to $1.3 million in the prior year.
	●	Gross margin was approximately 32% for the fiscal year 2026, compared to 39% for fiscal year 2025, reflecting the growing contribution of Alps’ aesthetic services business, which carries profit-sharing arrangements recorded within cost of sales, and a shift in overall revenue mix.
	●	Research and development expenses were $61,155 for the year ended March 31, 2026, compared to $169,987 for the year ended March 31, 2025, as Alps concentrated its research spending on priority programs — NK Cell Therapy (MyImmune), MYCELEST and mRNA diagnostics — and discontinued development of its COVID-19 mRNA vaccine candidate during the year.
	●	Other operating expenses increased to $1.2 million for the year ended March 31, 2026, compared to $1.1 million for the year ended March 31, 2025.
	●	Administrative expenses were $3.5 million for the year ended March 31, 2026, compared to $2.4 million for the year ended March 31, 2025. Professional fees relating to the Business Combination totaled $1,155,458, representing 33% of total administrative expenses for the year.

About Alps Group Inc

Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.

Forward-Looking Statements

Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

A further list and description of risks and uncertainties can be found in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026, filed with the SEC on August 6, 2026, and in other documents that the Company may file or furnish with the SEC, which you are encouraged to read. This press release should be read in conjunction with the audited consolidated and combined financial statements and related notes included in that Annual Report on Form 20-F. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

Investor Relations Contact

Philip Carlson

KCSA Strategic Communications

Phone: 212.896.1233

Email: Alps@kcsa.com

Comparison of Results of Operations for the Fiscal Years Ended March 31, 2026, 2025 and 2024

Basis of Presentation

The financial information in this press release is presented in U.S. dollars and has been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board. The Business Combination completed in October 2025 was accounted for as a capital reorganization. Percentages and dollar amount in the narrative above are rounded.

The following table summarizes the consolidated and combined results of operations for the fiscal years ended March 31, 2026, 2025 and 2024:

		2026				2025				2024
		USD				USD				USD
Revenue			4,856,320				3,371,037				2,403,552
Cost of sales			(3,298,046	)			(2,069,772	)			(1,804,622	)
Gross profit			1,558,274				1,301,265				598,930
Other operating income			1,331,816				31,282				49,977
Finance income			3,856				123				-
Distribution expenses			(205,601	)			(273,487	)			(160,855	)
Administrative expenses			(3,497,725	)			(2,400,790	)			(1,929,680	)
Other operating expenses			(1,235,928	)			(1,128,526	)			(917,524	)
Share results of associate			14,449				(10,760	)			3,421
			(2,030,859	)			(2,480,893	)			(2,355,731	)
Finance costs			(50,459	)			(48,283	)			(42,844	)
Loss before tax			(2,081,318	)			(2,529,176	)			(2,398,575	)
Income tax expense			(5,137	)			(95,562	)			7,414
Loss for the financial year			(2,086,455	)			(2,624,738	)			(2,391,161	)
Other comprehensive (loss)/income, net of income tax
Changes in fair value of other investment			(76,988	)			-				-
Foreign currency translation			(145,949	)			57,830				(121,298	)
Total comprehensive loss for the year			(2,345,525	)			(2,566,908	)			(2,512,459	)

Revenue

		2026				2025				2024
		USD				USD				USD
Cellular therapy			883,016				586,440				407,443
Medical testing, laboratory and aesthetics beauty services			3,149,193				2,617,110				1,755,910
Consultation fee			92,331				157,467				232,173
Sales of medicine and healthcare product			731,780				10,020				8,026
			4,856,320				3,371,037				2,403,552

Cash Flows for the Fiscal Year Ended March 31, 2026, 2025 and 2024

The following table sets forth a summary of our cash flow for the year ended March 31, 2026, 2025 and 2024:

		2026				2025				2024
		USD				USD				USD
Summary consolidated cash flows
Net cash used in operating activities			(2,575,649	)			(1,608,785	)			(1,366,743	)
Net cash used in investing activities			(64,490	)			(100,062	)			(1,714,272	)
Net cash generated from financing activities			2,931,489				1,866,596				3,278,576
Net increase in cash and cash equivalents			291,350				157,749				197,561
Effect of exchange differences			(2,809	)			(299,284	)			1,092
Cash and cash equivalents at beginning of year			318,932				460,467				261,814
Cash and cash equivalents at end of year			607,473				318,932				460,467

ALPS GROUP INC AND ITS SUBSIDIARIES

Consolidated and Combined Statements of Financial Position as at March 31, 2026 and 2025

(Audited)

		Note		2026				2025
				USD				USD
ASSETS
Non-Current Assets
Property, plant and equipment		5			2,161,206				2,378,025
Right-of-use assets		6			533,493				940,155
Intangible assets		7			616,569				728,313
Other investments		8			1,664,593				-
Investment in associates		9			18,606				1,596,176
Total Non-Current Assets					4,994,467				5,642,669
Current Assets
Inventories		10			492,877				556,215
Trade receivables		11			135,187				45,528
Other receivables, deposits and prepayments		12			423,665				295,015
Amount due from associates		13(b)(i)			27,393				18,435
Tax recoverable					288,328				256,843
Cash and bank balances					607,473				318,932
Total Current Assets					1,974,923				1,490,968
Total Assets					6,969,390				7,133,637
EQUITY AND LIABILITIES
Capital and Reserves
Share capital		14			16,640				580
Merger reserves		15			10,679,360				10,463,980
Accumulated losses					(13,173,667	)			(11,165,239	)
Fair value reserve		16			(76,988	)			-
Foreign translation reserve		17			(369,963	)			(187,881	)
Equity Attributable to the Owners of the Company					(2,924,618	)			(888,560	)
Non-controlling interests					(305,383	)			(227,356	)
Capital Deficiencies					(3,230,001	)			(1,115,916	)
Non-Current Liabilities
Amount due to directors		13(b)(ii)			4,398,453				-
Lease liabilities		18			176,410				738,245
Deferred tax liabilities		19			22,883				21,561
Warrant liability		20			125,528				-
Total Non-Current Liabilities					4,723,274				759,806
Current Liabilities
Trade payables		21			349,799				321,350
Other payables and accruals		22			3,455,153				878,421
Amount due to associates		13(b)(i)			132,468				20,763
Amount due to directors		13(b)(ii)			1,155,835				5,972,257
Lease liabilities		18			382,862				223,630
Tax liabilities					-				73,326
Total Current Liabilities					5,476,117				7,489,747
Total Liabilities					10,199,391				8,249,553
Total Equity and Liabilities					6,969,390				7,133,637

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 95.6 KB
• EX-99 GRAPHIC 16.4 KB